Galecto (GLTO) Competitors $4.61 -0.24 (-4.86%) As of 02/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GLTO vs. RNXT, LGVN, LVTX, TENX, CGTX, FNCH, DRRX, CARA, CTXR, and TRAWShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include RenovoRx (RNXT), Longeveron (LGVN), LAVA Therapeutics (LVTX), Tenax Therapeutics (TENX), Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), DURECT (DRRX), Cara Therapeutics (CARA), Citius Pharmaceuticals (CTXR), and Traws Pharma (TRAW). These companies are all part of the "pharmaceutical products" industry. Galecto vs. RenovoRx Longeveron LAVA Therapeutics Tenax Therapeutics Cognition Therapeutics Finch Therapeutics Group DURECT Cara Therapeutics Citius Pharmaceuticals Traws Pharma Galecto (NASDAQ:GLTO) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Does the MarketBeat Community prefer GLTO or RNXT? Galecto received 23 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 60.38% of users gave Galecto an outperform vote while only 47.37% of users gave RenovoRx an outperform vote. CompanyUnderperformOutperformGalectoOutperform Votes3260.38% Underperform Votes2139.62% RenovoRxOutperform Votes947.37% Underperform Votes1052.63% Do institutionals and insiders believe in GLTO or RNXT? 14.2% of Galecto shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 11.9% of Galecto shares are owned by insiders. Comparatively, 7.1% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is GLTO or RNXT more profitable? Galecto's return on equity of -76.96% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets GalectoN/A -76.96% -66.59% RenovoRx N/A -205.96%-110.01% Do analysts rate GLTO or RNXT? Galecto currently has a consensus target price of $10.00, indicating a potential upside of 117.16%. RenovoRx has a consensus target price of $9.00, indicating a potential upside of 773.79%. Given RenovoRx's higher probable upside, analysts clearly believe RenovoRx is more favorable than Galecto.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00RenovoRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor GLTO or RNXT? In the previous week, Galecto had 1 more articles in the media than RenovoRx. MarketBeat recorded 1 mentions for Galecto and 0 mentions for RenovoRx. Galecto's average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score. Company Overall Sentiment Galecto Neutral RenovoRx Neutral Which has more risk and volatility, GLTO or RNXT? Galecto has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Which has stronger earnings & valuation, GLTO or RNXT? RenovoRx is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectoN/AN/A-$38.35M-$19.14-0.24RenovoRxN/AN/A-$10.23M-$0.57-1.81 SummaryGalecto beats RenovoRx on 9 of the 12 factors compared between the two stocks. Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.37M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.245.8226.1519.13Price / SalesN/A268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book0.156.717.644.62Net Income-$38.35M$138.55M$3.19B$245.94M7 Day Performance-3.66%-2.63%-2.11%-2.62%1 Month Performance-16.27%-2.33%-0.49%-2.15%1 Year Performance-72.01%-5.33%16.44%12.95% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto3.1022 of 5 stars$4.61-4.9%$10.00+117.2%-73.3%$6.37MN/A-0.2440RNXTRenovoRx1.9 of 5 stars$1.04+1.0%$9.00+765.4%-24.3%$24.96MN/A-1.826High Trading VolumeLGVNLongeveron3.561 of 5 stars$1.67+6.4%$8.67+419.0%-70.5%$24.78M$1.89M-0.2720Upcoming EarningsNews CoveragePositive NewsLVTXLAVA Therapeutics2.9368 of 5 stars$0.94+0.8%$3.33+254.6%-50.9%$24.71M$7.35M-0.9160Gap UpTENXTenax Therapeutics1.9324 of 5 stars$7.20-1.4%$16.00+122.2%+55.2%$24.55MN/A0.009News CoverageGap UpCGTXCognition Therapeutics3.3333 of 5 stars$0.59+0.0%$8.30+1,306.5%-70.7%$24.52MN/A-0.6120News CoverageFNCHFinch Therapeutics GroupN/A$15.00-3.2%N/A+537.1%$24.09M$110,000.00-1.70190News CoverageHigh Trading VolumeDRRXDURECT3.3392 of 5 stars$0.77+2.5%$5.00+550.2%-10.9%$23.87M$8.55M-1.2680News CoverageCARACara Therapeutics3.7606 of 5 stars$5.20-7.1%$27.84+435.4%-38.8%$23.76M$20.97M-0.2580News CoverageCTXRCitius Pharmaceuticals2.8836 of 5 stars$2.69-0.4%$54.50+1,926.0%-90.6%$23.11MN/A-0.4520Earnings ReportAnalyst ForecastNews CoverageGap UpTRAWTraws Pharma0.5212 of 5 stars$6.21-7.3%N/AN/A$22.67M$230,000.00-0.0417News CoverageGap Down Related Companies and Tools Related Companies RenovoRx Competitors Longeveron Competitors LAVA Therapeutics Competitors Tenax Therapeutics Competitors Cognition Therapeutics Competitors Finch Therapeutics Group Competitors DURECT Competitors Cara Therapeutics Competitors Citius Pharmaceuticals Competitors Traws Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLTO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
